ORAL 5-AZACYTIDINE AND ROMIDEPSIN EXHIBIT MARKED ACTIVITY IN PATIENTS WITH PTCL: A MULTICENTER PHASE I STUDY.
O'Connor, Owen A; Falchi, Lorenzo; Lue, Jennifer K; Marchi, Enrica; Kinahan, Cristina; Sawas, Ahmed; Deng, Changchun; Montanari, Francesca; Amengual, Jennifer Effie; Kim, Hye A; Rada, Aishling M; Khan, Karen; Jacob, Alice T; Malanga, Michelle; Francescone, Mark; Nandakumar, Renu; Soderquist, Craig; Park, David C; Bhagat, Govind; Cheng, Bin; Risueno, Alberto; Menezes, Daniel; Shustov, Andrei R; Sokol, Lubomir; Scotto, Luigi.
; 2019 Aug 30.
Artigo em Inglês | MEDLINE | ID: mdl-31471376
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.
Phase I/II study of decitabine in patients with myelodysplastic syndrome: a multi-center study in Japan.
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
Thrombopoietin mimetics for patients with myelodysplastic syndromes.
The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes.
Myelodysplastic syndromes: Contemporary review and how we treat.
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.
Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
Diagnosis and treatment of juvenile myelomonocytic leukemia in Slovak Republic: novel approaches.